Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer characterized by late diagnosis and extensive metastasis. It is known to contain exclusively tumorigenic cancer stem cells (CSCs), which are resistant to chemotherapy like gemcitabine. We have previously shown that CD133+ CSCs contributes to disease progression and treatment failure in PDAC. In this study we demonstrate the therapeutic potential of novel dual BET/HDAC inhibitor TW09 to target CD133+ CSCs in a preclinical set-up.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
